Characterizing the induction of diabetes in juvenile cynomolgus monkeys with different doses of streptozotocin
详细信息 查看全文
- 作者：ChunLin Zou (1) (2) (3)
JiaYin Wang (1) (2)
ShuYan Wang (1) (2)
Fen Huang (4)
ZhenHua Ren (1) (2)
ZhiGuo Chen (1) (2)
Yu Zhang (1) (2) - 关键词：cynomolgus monkeys ; diabetes ; streptozotocin
- 刊名：Science China Life Sciences
- 出版年：2012
- 出版时间：March 2012
- 年：2012
- 卷：55
- 期：3
- 页码：210-218
- 全文大小：754KB
- 参考文献：1. Shapiro A M, Lakey J R, Ryan E A, / et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med, 2000, 343: 230-38 CrossRef
2. Xiao M, An L, Yang X, / et al. Establishing a human pancreatic stem cell line and transplanting induced pancreatic islets to reverse experimental diabetes in rats. Sci China Ser C-Life Sci, 2008, 51: 779-88 CrossRef
3. Jiang J, Au M, Lu K, / et al. Generation of insulin-producing islet-like clusters from human embryonic stem cells. Stem Cells, 2007, 25: 1940-953 CrossRef
4. D’Amour K A, Bang A G, Eliazer S, / et al. Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol, 2006, 24: 1392-401 CrossRef
5. Kroon E, Martinson L A, Kadoya K, / et al. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells / in vivo. Nat Biotechnol, 2008, 26: 443-52 CrossRef
6. Shapiro A M, Ricordi C, Hering B J, / et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med, 2006, 355: 1318-330 CrossRef
7. Contreras J L, Jenkins S, Eckhoff D E, / et al. Stable alpha- and beta-islet cell function after tolerance induction to pancreatic islet allografts in diabetic primates. Am J Transplant, 2003, 3: 128-38 CrossRef
8. Kishi Y, Tanaka Y, Shibata H, / et al. Variation in the incidence of teratomas after the transplantation of nonhuman primate ES cells into immunodeficient mice. Cell Transplant, 2008, 17: 1095-102 CrossRef
9. Kikutani H, Makino S. The murine autoimmune diabetes model: NOD and related strains. Adv Immunol, 1992, 51: 285-22 CrossRef
10. Greiner D L, Mordes J P, Handler E S, / et al. Prothymocyte development in diabetes-prone BB rats: description of a defect that predisposes to immune abnormalities. Transplant Proc, 1987, 19: 976-78
11. Kawano K, Hirashima T, Mori S, / et al. New inbred strain of Long-Evans Tokushima lean rats with IDDM without lymphopenia. Diabetes, 1991, 40: 1375-381 CrossRef
12. Cornblath D R, Dellon A L, MacKinnon S E. Spontaneous diabetes mellitus in a rhesus monkey: neurophysiological studies. Muscle Nerve, 1989, 12: 233-35 CrossRef
13. Sun Y, Ma X, Zhou D, / et al. Normalization of diabetes in spontaneously diabetic cynomolgus monkeys by xenografts of microencapsulated porcine islets without immunosuppression. J Clin Invest, 1996, 98: 1417-422 CrossRef
14. Wagner J D, Cline J M, Shadoan M K, / et al. Naturally occurring and experimental diabetes in cynomolgus monkeys: a comparison of carbohydrate and lipid metabolism and islet pathology. Toxicol Pathol, 2001, 29: 142-48 CrossRef
15. Lenzen S, Munday R. Thiol-group reactivity, hydrophilicity and stability of alloxan, its reduction products and its Nmethyl derivatives and a comparison with ninhydrin. Biochem Pharmacol, 1991, 42: 1385-391 CrossRef
16. Lenzen S, Tiedge M, Jorns A, / et al. Alloxan derivatives as a tool for elucidation of the mechanism of the diabetogonic action of alloxan. In: Lessons for Animal Diabetes. Shafrir E, ed. Boston: Birkhauser, 1996. 113-22 CrossRef
17. Gibbs G E, Wilson R B, Gifford H. Glomerulosclerosis in the long-term alloxan diabetic monkey. Diabetes, 1966, 15: 258-61
18. Bansal N, Majumdar S, Chakravarti R N. Frequency and size of atherosclerotic plaques in vasectomized diabetic monkeys. Int J Fertil, 1986, 31: 298-04
19. Theriault B R, Thistlethwaite J R, Levisetti M G, / et al. Induction, maintenance, and reversal of streptozotocin-induced insulin-dependent diabetes mellitus in the juvenile cynomolgus monkey ( / Macaca fascilularis). Transplantation, 1999, 68: 331-37 CrossRef
20. Koulmanda M, Qipo A, Chebrolu S, / et al. The effect of low versus high dose of streptozotocin in cynomolgus monkeys ( / Macaca fascilularis). Am J Transplant, 2003, 3: 267-72 CrossRef
21. van der Windt D J, Bottino R, Casu A, / et al. Long-term controlled normoglycemia in diabetic non-human primates after transplantation with hCD46 transgenic porcine islets. Am J Transplant, 2009, 9: 2716-726 CrossRef
22. Hecht G, Eventov-Friedman S, Rosen C, / et al. Embryonic pig pancreatic tissue for the treatment of diabetes in a nonhuman primate model. Proc Natl Acad Sci USA, 2009, 106: 8659-664 CrossRef
23. Bottino R, Criscimanna A, Casu A, / et al. Recovery of endogenous beta-cell function in nonhuman primates after chemical diabetes induction and islet transplantation. Diabetes, 2009, 58: 442-47 CrossRef
24. Casu A, Bottino R, Balamurugan A N, / et al. Metabolic aspects of pig-to-monkey ( / Macaca fascicularis) islet transplantation: implications for translation into clinical practice. Diabetologia, 2008, 51: 120-29 CrossRef
25. Shibata S, Kirchhof N, Matsumoto S, / et al. High-dose streptozotocin for diabetes induction in adult rhesus monkeys. Transplant Proc, 2002, 34: 1341-344 CrossRef
26. Thomas J M, Contreras J L, Smyth C A, / et al. Successful reversal of streptozotocin-induced diabetes with stable allogeneic islet function in a preclinical model of type 1 diabetes. Diabetes, 2001, 50: 1227-236 CrossRef
27. Rood P P, Bottino R, Balamurugan A N, / et al. Induction of diabetes in cynomolgus monkeys with high-dose streptozotocin: adverse effects and early responses. Pancreas, 2006, 33: 287-92 CrossRef
28. Wijkstrom M, Kirchhof N, Graham M, / et al. Cyclosporine toxicity in immunosuppressed streptozotocin-diabetic nonhuman primates. Toxicology, 2005, 207: 117-27 CrossRef
29. Ferraris R, Colombatti G, Fiorentini M T, / et al. Diagnostic value of serum bile acids and routine liver function tests in hepatobiliary diseases. Sensitivity, specificity and predictive value. Dig Dis Sci, 1983, 28: 129-36 - 作者单位：ChunLin Zou (1) (2) (3)
JiaYin Wang (1) (2)
ShuYan Wang (1) (2)
Fen Huang (4)
ZhenHua Ren (1) (2)
ZhiGuo Chen (1) (2)
Yu Zhang (1) (2)
1. Cell Therapy Center, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China
2. Key Laboratory of Neurogeneration, Ministry of Education, Beijing, 100053, China
3. Center for Translational Medicine, Guangxi Medical University, Guangxi, 530021, China
4. Guangxi Nanning Wincon TheraCells Biotechnologies Co., Guangxi, 530003, China
文摘
Juvenile (2-3 years old) cynomolgus monkeys are frequently used as recipients in non-human primate islet transplantation studies. The aim of this study was to examine the effects of different doses of streptozotocin (STZ), and find the optimal dose for inducing diabetes in these monkeys. Fifteen juvenile (2- years old) cynomolgus monkeys were separated into three groups and administered with different doses of STZ (100, 68 or 60 mg kg?). Basal and glucose-stimulated blood glucose, insulin, and C-peptide levels, as well as body weights were monitored. Hepatic and renal function tests and pancreatic immunohistochemistry were performed before and after STZ treatment. Monkeys treated with both 100 and 68 mg kg? of STZ exhibited continuous hyperglycemia, which coincided with a nearly complete loss of islet β-cells. Two monkeys received 60 mg kg? of STZ, but only one became completely diabetic. During the first week following STZ treatment, hepatic and renal function slightly increased in these three groups. However, 24 hours post-STZ, serum total bile acid levels were significantly increased in monkeys treated with 100 mg kg? than those treated with 68 mg kg? of STZ (P<0.05). These data suggest that 100 mg kg? and 68 mg kg? of STZ can safely induce diabetes in cynomolgus monkeys aged 2- years, but 68 mg kg? of STZ, rather than 100 mg kg? of STZ, may be more appropriate for inducing diabetes in these monkeys. Furthermore, body surface area, rather than body weight, was a more reliable determinant of dosage, where 700 mg m? of STZ should be the lower limit for inducing diabetes in juvenile monkeys.